Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis

Table 4

Univariate and multivariate analyses of factors associated with OS.

Clinical and pathologic indexes		Univariate		Multivariate
		HR (95% CI)		HR (95% CI)
Gender	(Male vs. female)	0.79 (0.51, 1.23)	0.30	N/A	N/A
Age, y	(≤50 vs. >50)	0.80 (0.60, 1.05)	0.11	N/A	N/A
HBsAg	(Positive vs. negative)	3.31 (2.49, 4.40)	0.00	1.52 (1.30, 1.78)	0.00
Liver cirrhosis	(No vs. yes)	0.79 (0.25, 2.48)	0.69	N/A	N/A
Portal lymph node	(Negative vs. positive)	0.54 (0.29, 1.03)	0.06	N/A	N/A
AFP (ng/ml)	(≤400 vs. >400)	2.33 (1.77, 3.06)	0.00	1.33 (1.15, 1.53)	0.00
MVI	(None vs. yes)	1.07 (0.79, 1.46)	0.65	N/A	N/A
Tumor number	(Multiple vs. single)	1.13 (0.83, 1.54)	0.45	N/A	N/A
Tumor size, cm	(≤5 vs. >5)	2.92 (2.16, 3.95)	0.00	1.51 (1.28, 1.79)	0.00
PVTT	(None vs. yes)	0.51 (0.39, 0.67)	0.00	0.99 (0.84, 1.16)	0.89
GGT (U/L)	(≤54 vs. >54)	1.48 (1.09, 2.01)	0.01	0.98 (0.83, 1.16)	0.85
Tumor encapsulation	(None vs. complete)	0.52 (0.39, 0.68)	0.00	0.82 (0.71, 0.96)	0.01
Edmondson stage	(II-IV vs. I-II)	0.87 (0.75, 1.00)	0.06	N/A	N/A
FOS	(Negative vs. positive)	0.69 (0.60, 0.79)	0.00	0.69 (0.60, 0.80)	0.00

AFP, α-fetoprotein; MVI, microvascular invasion; PVTT, portal vein tumor thrombus; GGT, γ-glutamyl transpeptidase; FOS, Fos protooncogene; HR, hazard ratio. Univariate analysis and multivariate analysis and cox proportional hazards regression model. and